Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q1 2021 Earnings Presentation
7 slides from Hls Therapeutics's earnings presentation, May 6, 2021
Slide 1: Q1 2021 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q1 2021 Results Conference Call May 6, 2021 TSX - HLS
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Canadian Cardiovascular Society adds Vascepa to its Lipid Management Guidelines
Canadian Cardiovascular Society adds Vascepa to its Lipid Management Guidelines “We recommend the use of icosapent ethyl to lower the risk of CV events in patients with ASCVD, or with diabetes and ≥1 CVD risk factors, who have an elevated fasting triglyceride level of 1.5-5.6 mmol/L despite treatmen
Slide 4: Vascepa: prescription momentum growing
Vascepa: prescription momentum growing… 400 Weekly script data since launch …despite a constrained environment 350 Gap in Patient Visits (all therapy classes in Canada) 300 250 Prescriptions 200 150 100 50 0 13-Mar-20 27-Mar-20 03-Jul-20 17-Jul-20 31-Jul-20 10-Apr-20 24-Apr-20 12-Mar-21 26-Mar-21 08
Slide 5: Vascepa Recent Analogues: two-year comparison
Vascepa Recent Analogues: two-year comparison Patients at 70K Peak 60K The oral anti-coagulant market is a relevant analogue for Vascepa. It has a similar market size potential and VASCEPA 130-150K 50K overlap of healthcare practitioners Projection (projected) Prescriptions 40K 290K 30K ELIQUIS (act
Slide 6: Q1 2021 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q1 2021 Results Conference Call May 6, 2021 TSX - HLS
Slide 7: Q&A
Q&A TSX - HLS